Back to Drug Candidates

Metformin

Glucophage

Biguanide / Complex I inhibitor / AMPK activator

Evidence Score

40

preclinical
Mechanism of Action

Inhibits mitochondrial Complex I, activates AMPK, and inhibits mTOR signaling. In SDH-deficient cells already lacking Complex II, additional Complex I inhibition may further disrupt mitochondrial metabolism. AMPK activation opposes mTOR-driven growth.

Pathway Connections
mTOR / PI3K / AKT

Metabolic reprogramming from SDH loss activates the PI3K/AKT/mTOR signaling axis, promoting cell growth, proliferation, and survival. Multiple upstream inputs converge on mTOR.

Upstream event:

HIF-mediated growth factor signaling + metabolic stress + AMPK dysregulation

Downstream effects:

Cell growth and proliferationProtein synthesisMetabolic reprogrammingSurvival signaling
Oxidative Stress / ROS

Complex II dysfunction causes electron leak in the electron transport chain, increasing reactive oxygen species (ROS). This drives DNA damage but also creates a therapeutic vulnerability.

Upstream event:

Impaired electron flow through Complex II → electron leak

Downstream effects:

Increased ROS productionOxidative DNA damageGenomic instabilityPARP activation for DNA repairTherapeutic vulnerability to further ROS stress
Molecular Targets

MTOR

Mechanistic target of rapamycin

downstream

Central growth/metabolism regulator activated downstream of SDH loss. Target of everolimus and temsirolimus.

UniProt: P42345

Quick Facts
FDA Approved

Approved Indications

  • Type 2 diabetes mellitus
ChEMBL IDCHEMBL1431
PubChem CID4091
Evidence

Evidence from PubMed, OpenTargets, and ChEMBL will appear here once external data integration is enabled.

Coming in Phase 3

AI Analysis

Have Claude analyze this drug's repurposing potential for SDH-deficient diseases.